This document provides a list of publications and patents by Christopher J. Aquino related to drug discovery across several therapeutic areas, including diabetes/obesity, cancer, HIV, and obesity. The list includes over 50 publications describing Aquino's work discovering and developing inhibitors of the ileal bile acid transporter, fatty acid synthase, CCR5 chemokine receptor, and reverse transcriptase for various indications. Additional publications cover Aquino's research on neuropeptide YY5 antagonists for obesity and cholecystokinin receptor agonists/antagonists for obesity and cancer.
The document summarizes key points from the 18th International Conference on Co-morbidities and Adverse Drug Reactions in HIV. It discusses findings related to bone health, cardiovascular health, and physical activity levels in people living with HIV. Regarding bone health, studies showed bone mineral density loss with tenofovir-containing antiretroviral therapy and PrEP. Loss was also seen with glucocorticoid use. For cardiovascular health, studies suggested lower risk of atherosclerotic events with NNRTI-based initial ART and possible lower risk with atazanavir. Physical activity levels were associated with comorbidity risk, with higher risk at lower activity levels.
Jennifer M. Sealy has authored or co-authored several publications including papers in peer-reviewed journals and patents. Some of her notable publications include papers in Bioorganic & Medicinal Chemistry Letters on the design and synthesis of brain penetrant JNK inhibitors for neurodegeneration prevention, and on the design of hydroxyethylamine BACE-1 inhibitors for Alzheimer's disease. She is also listed as an inventor on several patents related to the preparation of inhibitors for conditions like Alzheimer's.
This document discusses the potential health benefits of resveratrol based on scientific studies. It summarizes research showing that resveratrol may help prevent cancers, reduce cardiovascular risks, protect arteries, repair DNA damage, and prevent hepatic steatosis. The document recommends that taking resveratrol daily could provide benefits similar to stopping smoking, with low cost and no reported side effects.
This document provides an overview of chronic granulomatous disease (CGD), including its history, epidemiology, pathogenesis, and clinical features. CGD is a primary immunodeficiency caused by defects in the NADPH oxidase complex that generates superoxide in phagocytes. This impairs the ability to kill certain bacteria and fungi, leading to life-threatening infections. The condition was first described in the 1950s and genetic causes involving mutations in CYBB, CYBA, NCF1, NCF2, and NCF4 genes that encode phagocyte oxidase subunits were identified starting in the 1980s. CGD has an incidence of approximately 1 in 200,000 individuals.
The document lists 33 publications related to the preparation and testing of compounds that modulate cannabinoid receptors and inhibit kynurenine-3-monooxygenase. Many of the publications involve authors Celia Dominguez, Leticia Toledo-Sherman, Michael Prime, and William Mitchell. The publications span from 2005 to 2015 and include patents, journal articles, and conference presentations on developing therapies for neurodegenerative disorders and pain treatment.
This document discusses vitamin D deficiency in critical illness based on several studies. It finds that vitamin D deficiency is common in critically ill patients, with 100% of sepsis patients and 92% of non-sepsis ICU patients found to be vitamin D insufficient or deficient in one study. Low vitamin D levels are associated with higher illness severity and mortality. However, whether vitamin D replacement can improve outcomes in critical illness is still unclear due to challenges in dosing and administration in ICU patients. One study found a single high dose improved vitamin D levels in most patients.
This document provides a summary of a presentation on vitamin supplementation and essential nutrients. It discusses declining nutrient levels in foods and soils, the importance of antioxidants and micronutrients for health, and evidence that supplementation can help address deficiencies and support overall wellness. Studies are cited showing the benefits of supplements for conditions like cardiovascular health, testosterone levels, and depression.
This document discusses how moderate exercise affects natural killer (NK) cells through killer immunoglobulin-like receptors (KIRs). It explains that KIRs are receptors on NK cells that can be either activatory or inhibitory, and regulate NK cell cytotoxicity. Moderate exercise increases expression of the KIR2DS2 activatory receptor and KIR2DL3 inhibitory receptor on NK cells. This is mediated by increased levels of heat shock protein 70 (HSP70) from exercise, which activates a transcription factor that increases expression of these KIR genes. Upregulating these receptors promotes NK cell immune surveillance and effectiveness, demonstrating how exercise can benefit immune system function.
The document summarizes key points from the 18th International Conference on Co-morbidities and Adverse Drug Reactions in HIV. It discusses findings related to bone health, cardiovascular health, and physical activity levels in people living with HIV. Regarding bone health, studies showed bone mineral density loss with tenofovir-containing antiretroviral therapy and PrEP. Loss was also seen with glucocorticoid use. For cardiovascular health, studies suggested lower risk of atherosclerotic events with NNRTI-based initial ART and possible lower risk with atazanavir. Physical activity levels were associated with comorbidity risk, with higher risk at lower activity levels.
Jennifer M. Sealy has authored or co-authored several publications including papers in peer-reviewed journals and patents. Some of her notable publications include papers in Bioorganic & Medicinal Chemistry Letters on the design and synthesis of brain penetrant JNK inhibitors for neurodegeneration prevention, and on the design of hydroxyethylamine BACE-1 inhibitors for Alzheimer's disease. She is also listed as an inventor on several patents related to the preparation of inhibitors for conditions like Alzheimer's.
This document discusses the potential health benefits of resveratrol based on scientific studies. It summarizes research showing that resveratrol may help prevent cancers, reduce cardiovascular risks, protect arteries, repair DNA damage, and prevent hepatic steatosis. The document recommends that taking resveratrol daily could provide benefits similar to stopping smoking, with low cost and no reported side effects.
This document provides an overview of chronic granulomatous disease (CGD), including its history, epidemiology, pathogenesis, and clinical features. CGD is a primary immunodeficiency caused by defects in the NADPH oxidase complex that generates superoxide in phagocytes. This impairs the ability to kill certain bacteria and fungi, leading to life-threatening infections. The condition was first described in the 1950s and genetic causes involving mutations in CYBB, CYBA, NCF1, NCF2, and NCF4 genes that encode phagocyte oxidase subunits were identified starting in the 1980s. CGD has an incidence of approximately 1 in 200,000 individuals.
The document lists 33 publications related to the preparation and testing of compounds that modulate cannabinoid receptors and inhibit kynurenine-3-monooxygenase. Many of the publications involve authors Celia Dominguez, Leticia Toledo-Sherman, Michael Prime, and William Mitchell. The publications span from 2005 to 2015 and include patents, journal articles, and conference presentations on developing therapies for neurodegenerative disorders and pain treatment.
This document discusses vitamin D deficiency in critical illness based on several studies. It finds that vitamin D deficiency is common in critically ill patients, with 100% of sepsis patients and 92% of non-sepsis ICU patients found to be vitamin D insufficient or deficient in one study. Low vitamin D levels are associated with higher illness severity and mortality. However, whether vitamin D replacement can improve outcomes in critical illness is still unclear due to challenges in dosing and administration in ICU patients. One study found a single high dose improved vitamin D levels in most patients.
This document provides a summary of a presentation on vitamin supplementation and essential nutrients. It discusses declining nutrient levels in foods and soils, the importance of antioxidants and micronutrients for health, and evidence that supplementation can help address deficiencies and support overall wellness. Studies are cited showing the benefits of supplements for conditions like cardiovascular health, testosterone levels, and depression.
This document discusses how moderate exercise affects natural killer (NK) cells through killer immunoglobulin-like receptors (KIRs). It explains that KIRs are receptors on NK cells that can be either activatory or inhibitory, and regulate NK cell cytotoxicity. Moderate exercise increases expression of the KIR2DS2 activatory receptor and KIR2DL3 inhibitory receptor on NK cells. This is mediated by increased levels of heat shock protein 70 (HSP70) from exercise, which activates a transcription factor that increases expression of these KIR genes. Upregulating these receptors promotes NK cell immune surveillance and effectiveness, demonstrating how exercise can benefit immune system function.
Endocrine Disruption of the Neuro-immune InterfaceDES Daughter
The document discusses the neuro-immune interface and how endocrine disrupting chemicals (EDCs) can impact the interactions between the nervous, immune, and endocrine systems, especially during development. It provides an example showing that hormone disruption during sensitive prenatal and early postnatal periods can influence brain sex development and adult sexual behavior through effects on immune cells in the brain called microglia. The summary concludes that more research is still needed to understand how EDC exposures may impact development by disrupting the complex interactions between the body's key regulatory systems during critical windows.
This document discusses possible links between vitamin D deficiency and various geriatric syndromes and common comorbidities. It begins by outlining how vitamin D receptors are present in many tissues beyond the musculoskeletal system. It then examines potential associations between vitamin D deficiency and increased risks of frailty, urinary incontinence, dementia/cognitive impairment, and depression in elderly populations. While evidence is limited and relationships are not clearly causal, several observational studies have found correlations between low vitamin D levels and higher rates of these conditions. More research is still needed, but maintaining adequate vitamin D status may help reduce risks of age-related diseases and functional decline.
1) The document discusses vitamin D deficiency and its link to various health issues. It reports that 61-82% of postmenopausal women and 98% of patients with osteoporotic fractures have inadequate vitamin D levels.
2) Several causes of vitamin D deficiency in the elderly are described, including lack of sun exposure and less effective vitamin D synthesis in the skin.
3) The text reviews results from studies that show vitamin D supplementation can reduce fracture risk by 33%, falling risk by 49%, and improve lower limb function. It is suggested that maintaining higher vitamin D levels may provide significant economic savings in healthcare costs.
In this presentation, Dr. Cady builds on previous lectures dealing with anti-oxidants and vitamin, mineral, and soil depletion to add discussions of vinpocetine and Bacopa monieri, as well as a discussion of the Medhya Rasayana approach from centuries old Aryuvedic practice in India. There is an emphasis on obtaining solid multivitamin, multi-mineral, and antioxidant support. References for two supplements lines (Physiologics and Metagenics) are given.
This document summarizes research on aging and anti-aging compounds conducted by Dr. David Sinclair, a leading anti-aging scientist. It discusses that Dr. Sinclair discovered that the compound resveratrol can activate the Sirtuin 1 gene to mimic calorie restriction and extend lifespan. Resveratrol was found to promote longevity in yeast cells. The document also introduces a product called Vivix, which is claimed to activate genetic regulators and help turn down cellular aging through ingredients that support cell defense, energy, repair and performance.
Shaklee Vivix slows aging at the cellular level. Plug in and learn the story behind scenes. To hear the live presentation contact Cindy McAsey 888-272-6701/
Osteogenesis Imperfecta is a genetic connective tissue disorder. It has clinically heterogeneous four types. Type 2 is the most severe and perinatally lethal form having small thorax, curved limbs and blue/gray sclerae. It is further subclassified into 3 types. A baby with sign and symptoms with macrocephaly, retrognathia, low set ears, widely placed eyes with white sclerae, complete cleft palate, narrow chest, curved and shortened limbs, B/L CTEV, left undescended testis with hypospadiasis was reported. This rare case was thoroghly examined and investigated which came out to a case of 'Osteogenesis Imperfecta type 2 A' having white sclerae. So case having such symptoms were should be investigated for Osteogenesis Imperfecta.
This document provides a list of publications by Jennifer M. Sealy including 10 papers published in Bioorganic & Medicinal Chemistry Letters between 2010-2011 related to the design and synthesis of inhibitors for neurodegeneration. It also lists 4 patents with Sealy as an inventor related to the preparation of inhibitors for treating conditions like Alzheimer's disease.
1. This document lists original articles and book chapters published by Dr. Lee BC and collaborators related to hematopoietic stem cells and cancer.
2. The publications span from 1988 to 2017 and cover topics such as the role of specific genes and receptors in regulating hematopoietic stem cells and their response to stressors like radiation.
3. Many of the articles examine how the bone marrow microenvironment influences hematopoietic stem cells through factors secreted by other cell types.
This document provides an overview of Autoimmune Polyendocrinopathy-Candidiasis–Ectodermal Dysplasia (APECED), also known as Autoimmune Polyendocrinopathy Syndrome Type 1 (APS-1). It discusses the epidemiology, pathogenesis, clinical manifestations, diagnosis, and management. The pathogenesis involves mutations in the autoimmune regulator (AIRE) gene leading to loss of central tolerance and autoimmunity against various endocrine and other tissues. Common clinical manifestations include chronic mucocutaneous candidiasis, hypoparathyroidism, adrenal insufficiency, and others. Diagnosis is based on clinical criteria and AIRE gene mutation analysis can confirm. Management requires treatment of
This document summarizes hyper IgE syndrome, a rare genetic disorder characterized by recurrent skin and lung infections and extremely high levels of IgE antibodies. It exists in two forms - autosomal dominant and autosomal recessive - caused by mutations in the STAT3, DOCK8, and TYK2 genes. The autosomal dominant form presents with eczema, lung infections, characteristic facial features, bone fractures, and serum IgE over 2000 IU/ml. The autosomal recessive forms, caused by DOCK8 and TYK2 mutations, present similarly but without bone or facial abnormalities. Diagnosis involves clinical features, genetic testing, and immunological abnormalities like low Th17 cells. Treatment focuses on long-
The document discusses the causes and treatments of various infectious diseases including Zika virus, dengue fever, yellow fever, and syphilis. It describes how Zika virus originated in monkeys in Africa and has spread to humans around the world through human travel. It also explains how mosquitos act as vectors, spreading the diseases by biting infected humans and other animals. The document proposes treatments for Zika and dengue fever that were used successfully in Vietnam in the 1960s, involving antibiotics and corticosteroids to fight secondary infections and reduce inflammation.
Bill Faloon Age Reversal Update at DaVinci 50 Masters Conference 2021maximuspeto
In this presentation, Bill Faloon gives an update on the prospects for human age reversal medicine at the DaVinci 50 Masters Conference in Key Largo, Florida on April 29th, 2021.
This editorial discusses three studies that found an association between fish/omega-3 fatty acid consumption and reduced risk of cognitive decline and Alzheimer's disease. Specifically, the Framingham Heart Study found those in the top quartile of DHA levels had a 47% lower dementia risk. The Zutphen Elderly Study found less cognitive decline in fish consumers, and a linear relationship between DHA/EPA intake and prevention of decline. The Minneapolis study found higher DHA/EPA associated with lower risk of cognitive decline in those with hypertension/dyslipidemia. The studies provide rationale for future clinical trials of fish/fish oil on Alzheimer's disease prevention.
This document summarizes the relationship between antioxidants, telomeres, aging, and disease. It discusses how free radicals cause oxidative damage that leads to cellular aging and death. Antioxidants can neutralize free radicals and protect telomeres, the protective caps at the end of chromosomes. Shortened telomeres are associated with aging and disease as cells can no longer divide. Compounds in Moringa oleifera like vitamins A, C, E, and selenium act as antioxidants that may protect telomeres from oxidative damage and slow cellular aging.
Bill Faloon at DaVinci 50 about stroke risk and blood pressuremaximuspeto
In this presentation on Thursday April 29th, 2021 at the DaVinci 50 Mastermind Conference in Key Largo, Florida, Bill Faloon discusses how to optimize blood pressure to reduce stroke risk.
This document is a curriculum vitae for Lei Li, a professor at the State Key Laboratory of Stem Cell and Reproductive Biology at the Chinese Academy of Sciences. It outlines her education, degrees, professional experience, awards, publications, and invited presentations. She received her PhD from Gunma University in Japan and has held positions at several institutions in China, Japan, and the United States. Her research focuses on early mouse embryonic development and diabetes.
This study found that flies expressing the human amyloid-b peptide (Ab42) in neurons exhibited significantly reduced consolidated sleep compared to control flies. When these Ab42 flies also expressed either the Drosophila or mammalian fatty acid binding protein (Fabp) transgene, they showed a significant increase in nighttime sleep and longer consolidated sleep bouts, rescuing the sleep disruption caused by Ab42. This suggests that Ab42 expression alone can disrupt sleep consolidation, and that Fabp expression may help mitigate Ab42-induced sleep disturbances, as seen in Alzheimer's disease patients. Understanding these relationships between Ab42, Fabp, and sleep could aid in developing therapies to delay Alzheimer's disease progression.
New biochemical markers of risk of Coronary Heart Disease (CHD)meducationdotnet
This document discusses the use of high-sensitivity C-reactive protein (hsCRP) as a biomarker for predicting cardiovascular disease risk. It notes that traditional risk factors have low sensitivity and specificity. HsCRP is emerging as a stronger predictor of risk than LDL and can help reclassify some patients as higher risk. Larger studies like the JUPITER trial are investigating using hsCRP levels to determine who may benefit from statin therapy independent of LDL levels. While hsCRP shows promise, more research is still needed to understand genetic and other factors that may influence hsCRP levels and risk predictions.
This document lists invited presentations, publications, and patent applications by Rikki Alexander related to pharmaceutical research. It includes presentations on phosphodiesterase inhibitors for asthma treatment from 2002-2003. It also lists several patent applications and publications from 2008-2015 on small molecule inhibitors for conditions like TNF activity and PI3 kinase. The publications involve collaborations and are focused on developing drug candidates and understanding disease mechanisms.
The laboratory focuses on developing drug delivery systems using biomaterials like hyaluronic acid. A thermosensitive injectable hydrogel was created using nanocomplexes of doxorubicin and hyaluronic acid for local cancer treatment. This hydrogel inhibited cancer cell growth and selectively targeted the lymphatic system due to hyaluronic acid's affinity for the lymphatic system. The lab is also exploring combination therapy delivery systems, such as a thermosensitive hydrogel incorporating doxorubicin and docetaxel-loaded nanoparticles for overcoming drug resistance in tumors.
Daryl Walter has authored or co-authored 30 publications and patents from 2006 to 2009 related to pharmaceutical research. His publications focus on developing treatments for conditions like Alzheimer's disease, pain, and inflammation by modulating the P2X7 receptor and developing BACE-1 inhibitors. His work involved synthesizing new classes of drug-like molecules and characterizing their pharmacological properties.
Endocrine Disruption of the Neuro-immune InterfaceDES Daughter
The document discusses the neuro-immune interface and how endocrine disrupting chemicals (EDCs) can impact the interactions between the nervous, immune, and endocrine systems, especially during development. It provides an example showing that hormone disruption during sensitive prenatal and early postnatal periods can influence brain sex development and adult sexual behavior through effects on immune cells in the brain called microglia. The summary concludes that more research is still needed to understand how EDC exposures may impact development by disrupting the complex interactions between the body's key regulatory systems during critical windows.
This document discusses possible links between vitamin D deficiency and various geriatric syndromes and common comorbidities. It begins by outlining how vitamin D receptors are present in many tissues beyond the musculoskeletal system. It then examines potential associations between vitamin D deficiency and increased risks of frailty, urinary incontinence, dementia/cognitive impairment, and depression in elderly populations. While evidence is limited and relationships are not clearly causal, several observational studies have found correlations between low vitamin D levels and higher rates of these conditions. More research is still needed, but maintaining adequate vitamin D status may help reduce risks of age-related diseases and functional decline.
1) The document discusses vitamin D deficiency and its link to various health issues. It reports that 61-82% of postmenopausal women and 98% of patients with osteoporotic fractures have inadequate vitamin D levels.
2) Several causes of vitamin D deficiency in the elderly are described, including lack of sun exposure and less effective vitamin D synthesis in the skin.
3) The text reviews results from studies that show vitamin D supplementation can reduce fracture risk by 33%, falling risk by 49%, and improve lower limb function. It is suggested that maintaining higher vitamin D levels may provide significant economic savings in healthcare costs.
In this presentation, Dr. Cady builds on previous lectures dealing with anti-oxidants and vitamin, mineral, and soil depletion to add discussions of vinpocetine and Bacopa monieri, as well as a discussion of the Medhya Rasayana approach from centuries old Aryuvedic practice in India. There is an emphasis on obtaining solid multivitamin, multi-mineral, and antioxidant support. References for two supplements lines (Physiologics and Metagenics) are given.
This document summarizes research on aging and anti-aging compounds conducted by Dr. David Sinclair, a leading anti-aging scientist. It discusses that Dr. Sinclair discovered that the compound resveratrol can activate the Sirtuin 1 gene to mimic calorie restriction and extend lifespan. Resveratrol was found to promote longevity in yeast cells. The document also introduces a product called Vivix, which is claimed to activate genetic regulators and help turn down cellular aging through ingredients that support cell defense, energy, repair and performance.
Shaklee Vivix slows aging at the cellular level. Plug in and learn the story behind scenes. To hear the live presentation contact Cindy McAsey 888-272-6701/
Osteogenesis Imperfecta is a genetic connective tissue disorder. It has clinically heterogeneous four types. Type 2 is the most severe and perinatally lethal form having small thorax, curved limbs and blue/gray sclerae. It is further subclassified into 3 types. A baby with sign and symptoms with macrocephaly, retrognathia, low set ears, widely placed eyes with white sclerae, complete cleft palate, narrow chest, curved and shortened limbs, B/L CTEV, left undescended testis with hypospadiasis was reported. This rare case was thoroghly examined and investigated which came out to a case of 'Osteogenesis Imperfecta type 2 A' having white sclerae. So case having such symptoms were should be investigated for Osteogenesis Imperfecta.
This document provides a list of publications by Jennifer M. Sealy including 10 papers published in Bioorganic & Medicinal Chemistry Letters between 2010-2011 related to the design and synthesis of inhibitors for neurodegeneration. It also lists 4 patents with Sealy as an inventor related to the preparation of inhibitors for treating conditions like Alzheimer's disease.
1. This document lists original articles and book chapters published by Dr. Lee BC and collaborators related to hematopoietic stem cells and cancer.
2. The publications span from 1988 to 2017 and cover topics such as the role of specific genes and receptors in regulating hematopoietic stem cells and their response to stressors like radiation.
3. Many of the articles examine how the bone marrow microenvironment influences hematopoietic stem cells through factors secreted by other cell types.
This document provides an overview of Autoimmune Polyendocrinopathy-Candidiasis–Ectodermal Dysplasia (APECED), also known as Autoimmune Polyendocrinopathy Syndrome Type 1 (APS-1). It discusses the epidemiology, pathogenesis, clinical manifestations, diagnosis, and management. The pathogenesis involves mutations in the autoimmune regulator (AIRE) gene leading to loss of central tolerance and autoimmunity against various endocrine and other tissues. Common clinical manifestations include chronic mucocutaneous candidiasis, hypoparathyroidism, adrenal insufficiency, and others. Diagnosis is based on clinical criteria and AIRE gene mutation analysis can confirm. Management requires treatment of
This document summarizes hyper IgE syndrome, a rare genetic disorder characterized by recurrent skin and lung infections and extremely high levels of IgE antibodies. It exists in two forms - autosomal dominant and autosomal recessive - caused by mutations in the STAT3, DOCK8, and TYK2 genes. The autosomal dominant form presents with eczema, lung infections, characteristic facial features, bone fractures, and serum IgE over 2000 IU/ml. The autosomal recessive forms, caused by DOCK8 and TYK2 mutations, present similarly but without bone or facial abnormalities. Diagnosis involves clinical features, genetic testing, and immunological abnormalities like low Th17 cells. Treatment focuses on long-
The document discusses the causes and treatments of various infectious diseases including Zika virus, dengue fever, yellow fever, and syphilis. It describes how Zika virus originated in monkeys in Africa and has spread to humans around the world through human travel. It also explains how mosquitos act as vectors, spreading the diseases by biting infected humans and other animals. The document proposes treatments for Zika and dengue fever that were used successfully in Vietnam in the 1960s, involving antibiotics and corticosteroids to fight secondary infections and reduce inflammation.
Bill Faloon Age Reversal Update at DaVinci 50 Masters Conference 2021maximuspeto
In this presentation, Bill Faloon gives an update on the prospects for human age reversal medicine at the DaVinci 50 Masters Conference in Key Largo, Florida on April 29th, 2021.
This editorial discusses three studies that found an association between fish/omega-3 fatty acid consumption and reduced risk of cognitive decline and Alzheimer's disease. Specifically, the Framingham Heart Study found those in the top quartile of DHA levels had a 47% lower dementia risk. The Zutphen Elderly Study found less cognitive decline in fish consumers, and a linear relationship between DHA/EPA intake and prevention of decline. The Minneapolis study found higher DHA/EPA associated with lower risk of cognitive decline in those with hypertension/dyslipidemia. The studies provide rationale for future clinical trials of fish/fish oil on Alzheimer's disease prevention.
This document summarizes the relationship between antioxidants, telomeres, aging, and disease. It discusses how free radicals cause oxidative damage that leads to cellular aging and death. Antioxidants can neutralize free radicals and protect telomeres, the protective caps at the end of chromosomes. Shortened telomeres are associated with aging and disease as cells can no longer divide. Compounds in Moringa oleifera like vitamins A, C, E, and selenium act as antioxidants that may protect telomeres from oxidative damage and slow cellular aging.
Bill Faloon at DaVinci 50 about stroke risk and blood pressuremaximuspeto
In this presentation on Thursday April 29th, 2021 at the DaVinci 50 Mastermind Conference in Key Largo, Florida, Bill Faloon discusses how to optimize blood pressure to reduce stroke risk.
This document is a curriculum vitae for Lei Li, a professor at the State Key Laboratory of Stem Cell and Reproductive Biology at the Chinese Academy of Sciences. It outlines her education, degrees, professional experience, awards, publications, and invited presentations. She received her PhD from Gunma University in Japan and has held positions at several institutions in China, Japan, and the United States. Her research focuses on early mouse embryonic development and diabetes.
This study found that flies expressing the human amyloid-b peptide (Ab42) in neurons exhibited significantly reduced consolidated sleep compared to control flies. When these Ab42 flies also expressed either the Drosophila or mammalian fatty acid binding protein (Fabp) transgene, they showed a significant increase in nighttime sleep and longer consolidated sleep bouts, rescuing the sleep disruption caused by Ab42. This suggests that Ab42 expression alone can disrupt sleep consolidation, and that Fabp expression may help mitigate Ab42-induced sleep disturbances, as seen in Alzheimer's disease patients. Understanding these relationships between Ab42, Fabp, and sleep could aid in developing therapies to delay Alzheimer's disease progression.
New biochemical markers of risk of Coronary Heart Disease (CHD)meducationdotnet
This document discusses the use of high-sensitivity C-reactive protein (hsCRP) as a biomarker for predicting cardiovascular disease risk. It notes that traditional risk factors have low sensitivity and specificity. HsCRP is emerging as a stronger predictor of risk than LDL and can help reclassify some patients as higher risk. Larger studies like the JUPITER trial are investigating using hsCRP levels to determine who may benefit from statin therapy independent of LDL levels. While hsCRP shows promise, more research is still needed to understand genetic and other factors that may influence hsCRP levels and risk predictions.
This document lists invited presentations, publications, and patent applications by Rikki Alexander related to pharmaceutical research. It includes presentations on phosphodiesterase inhibitors for asthma treatment from 2002-2003. It also lists several patent applications and publications from 2008-2015 on small molecule inhibitors for conditions like TNF activity and PI3 kinase. The publications involve collaborations and are focused on developing drug candidates and understanding disease mechanisms.
The laboratory focuses on developing drug delivery systems using biomaterials like hyaluronic acid. A thermosensitive injectable hydrogel was created using nanocomplexes of doxorubicin and hyaluronic acid for local cancer treatment. This hydrogel inhibited cancer cell growth and selectively targeted the lymphatic system due to hyaluronic acid's affinity for the lymphatic system. The lab is also exploring combination therapy delivery systems, such as a thermosensitive hydrogel incorporating doxorubicin and docetaxel-loaded nanoparticles for overcoming drug resistance in tumors.
Daryl Walter has authored or co-authored 30 publications and patents from 2006 to 2009 related to pharmaceutical research. His publications focus on developing treatments for conditions like Alzheimer's disease, pain, and inflammation by modulating the P2X7 receptor and developing BACE-1 inhibitors. His work involved synthesizing new classes of drug-like molecules and characterizing their pharmacological properties.
Daryl Walter is an expert in drug discovery and development, with publications and patents spanning various therapeutic areas. Some of his work includes:
1) Developing novel P2X7 receptor modulators to treat pain and neurodegeneration through publications characterizing the receptor and novel chemical classes acting on it.
2) Discovering new BACE-1 inhibitors for Alzheimer's through structure activity relationship studies leading to drug candidates with improved potency and pharmacokinetics.
3) Designing and synthesizing novel heterocyclic chemical scaffolds and optimizing drug-like properties through medicinal chemistry.
Daryl Walter has authored or co-authored 34 publications and patents related to P2X7 receptor modulators and BACE-1 inhibitors. The publications describe the synthesis and testing of various chemical derivatives to modulate the P2X7 receptor, including imidazoles, pyrazoles, piperazines, and morpholines. Additional work involved optimizing hydroxyethylamine inhibitors of the BACE-1 enzyme for treatment of Alzheimer's disease.
This document is a curriculum vitae for Dr. Avi L. Friedlich summarizing his personal and educational background, academic positions held, research support and medical certification, professional memberships, honors and awards, publications, and editorial experience. It details that he received a B.S. from UCLA and an M.D. from Case Western Reserve University, held various academic and research positions at institutions including Harvard Medical School and MIT, has over 50 publications in peer-reviewed journals, and has received several honors and awards for his research work.
The document lists publications from researchers including Nixon, Gibbons, Berry, Ward, and O'Neill. Many of the publications are manuscripts in preparation or published papers describing the discovery, design, and evaluation of new drug candidates targeting malaria and tuberculosis. The publications cover a range of topics including arylamine quinolones, heterocyclic quinolones, bisaryl quinolones, endoperoxide-falcipain inhibitors, and other antimalarial compounds.
The document provides a summary of the qualifications and experience of David C. Crosby, Ph.D. It includes his contact information and outlines his experience in medical science liaison roles in infectious disease, as well as his background in virology research. It also lists his education, publications, presentations, and professional affiliations.
The document summarizes the research of Prof. Chieh-Hsi Wu, who focuses on pathological mechanisms involved in restenosis progression and evaluations of bioactive compounds for treating restenosis, hyperlipidemia, and cancer. His laboratory uses genomic and proteomic analyses to identify molecules involved in restenosis development and potential therapeutic targets. He evaluates natural compounds for preventing restenosis and hyperlipidemia.
These clinical practice guidelines were developed by a task force consisting of experts from the American College of Critical Care Medicine, the Society of Critical Care Medicine, the American Society of Health-System Pharmacists, and the American College of Chest Physicians. The guidelines provide recommendations for the sustained use of sedatives and analgesics in critically ill adult patients.
This document provides a summary of William J. Frazee's professional background and qualifications, including:
- Patents on ion channel modulators and blockers that Frazee co-authored.
- Publications in peer-reviewed journals on topics like drug screening assays and kinase inhibitors.
- Conference posters and presentations given by Frazee and collaborators on developing fluorescence-based screening assays.
- Contact information for William J. Frazee including address, phone numbers, and email.
This document is an edited volume on dioxins and health that contains 22 chapters contributed by experts in various related fields. It provides an overview of the current state of knowledge regarding the production, distribution, fate, and measurement of dioxins in the environment and food. It also examines the toxicology, dose-response modeling, immunotoxicity, developmental and reproductive effects of dioxin exposure. Additional chapters analyze epidemiological studies on cancer and exposure, reproductive health consequences, case studies of major dioxin accidents and incidents, and the involvement of the aryl hydrocarbon receptor in dioxin toxicity. The volume aims to inform readers about the health risks of dioxins and related compounds.
David C. Crosby is a medical science liaison with over 15 years of experience in infectious disease research and medical communications. He has worked at several biotech companies, including his current role at Melinta Therapeutics where he engages with key opinion leaders to discuss Melinta's antibiotic pipeline. Crosby also has a background in virology research, having conducted HIV/AIDS studies at the University of California, San Francisco and the University of California, Irvine where he received his Ph.D. He is experienced in scientific engagement, competitive intelligence gathering, and distilling medical information for commercial and clinical functions.
Article critiques ( Min 1500 words) Styles of leadership. .docxdavezstarr61655
Article critiques :( Min 1500 words)
Styles of leadership.
Note :-( Rules for submission) The structure includes:
• Title – informs us it is a review
• Informative Abstract – informs us this is a meta-analysis (novel analysis in a novel context of previously published data)
• Introduction
• Body – Material & Methods, Results (including the use of tables and figures to display novel findings), Discussion
• Conclusion – a listing of novel findings of the meta-analysis
• References – organized alphabetically
1. Abstract On your abstract page, center the word “Abstract” at the top of the page without any additional formatting.
On the next line, write a concise summary of your critique. This should be a brief summary about the article and your critique. Examples of points to make in this paragraph include objectively analyzing the article and evaluating its contributions to learning. This paragraph should be between 150 to 250 words.
2. Main Body Type your title at the top of the page without any additional formatting. Following a double space, begin writing your critique. Journal critiques analyze a variety of topics. Examples of issues you may want to include in this section include whether you found any errors of fact or interpretation, the author was objective.
Choose one of the following subjects:
1-Bureaucratic Leadership
2-Charismatic Leadership
3-Servant Leadership
4-Transactional Leadership
References
Bacco, Alessandra Di, and Grace Gill. "The Secreted Glycoprotein CREG Inhibits Cell Growth Dependent on the Mannose-6-phosphate|[sol]|insulin-like Growth Factor II Receptor." Nature News. Nature Publishing Group, 21 Aug. 2003.
Bauer, Matthias, Anne C. Hamm, Melanie Bonaus, Andrea Jacob, Jens Jaekel, Hubert Schorle, Michael J. Pankratz, and Joerg D. Katzenberger. "Starvation Response in Mouse Liver Shows Strong Correlation with Life-span-prolonging Processes." Physiological Genomics. American Physiological Society, 13 Apr. 2004.
Briers, Demarcus. "Liver: Cell Types Found in Liver Simplified." DBrierscom. N.p., 20 Sept. 2012.
Bulla, Gary A. "Selective Loss of the Hepatic Phenotype Due to the Absence of a Transcriptional Activation Pathway." Somatic Cell and Molecular Genetics, 7 Mar. 1997.
Bulla, Gary. "Extinction of Alpha1-antitrypsin Expression in Cell Hybrids Is Independent of HNF1alpha and HNF4 and Involves Both Promoter and Internal DNA Sequences." Nucleic Acids Research 27 April. 1999. 1190-197.
Bulla, Gary A., Caitlin M. Aylmer, Adele L. Dust, Jeffrey L. Kurkewich, Leon K. Mire, and Arnold B. Estanda. "Genome-wide Analysis of Hepatic Gene Silencing in Hepatoma Cell Variants." Genomics 100.3 (2012): 176-83.
Bustin, Stephens. “Absolute Quantification of mRNA Using Real-Time Reverse Transcription Polymerase Chain Reaction Assays.” Journal of Molecular Endocrinology 25 (2000): 169–193.
Castell James and Gomez-Lechon John. “Liver Cell Culture Techniques.” Methods in Molecular Biology 481 (2009): 36-46.
.
This document summarizes a proposed experiment to increase RELN transcription in reeler mice by delivering the Tbr1 transcription activator using exosome treatment. The experiment involves isolating the Tbr1 gene from healthy mouse brain tissue, amplifying it via PCR, recombining it into a pUC19 plasmid, transforming E. coli with the plasmid to produce purified Tbr1 protein, and injecting the protein into exosomes derived from dendritic cells. The exosomes would then be administered to cultured reeler mouse brain tissue and to reeler mice via nasal spray to potentially increase RELN expression, improve neural connectivity, and alleviate schizophrenic symptoms. The results would be analyzed using microarrays and behavioral observations.
James J. Campbell has had an extensive career in immunology research. He is currently a Senior Director at ChemoCentryx, where he leads pre-clinical research teams investigating drug mechanisms of action. Previously, he was a Principal Investigator and Professor at Harvard Medical School, where he managed an immunology lab and published over 60 peer-reviewed papers. He has received many awards and honors for his research and expertise in T cell biology, chemokines, and skin and intestinal immunity.
This document provides a summary of the qualifications and experience of Francesca Madiai, PhD. She has over 10 years of experience as a clinical research coordinator, with expertise in areas such as project planning, data collection, protocol development, and GCP compliance. Her background includes a PhD in Molecular, Cellular and Developmental Biology from Ohio State University and over 10 publications in scientific journals. She has coordinated over 50 clinical trials in rheumatology and has experience with regulatory submissions, study execution, and patient recruitment.
This document provides a publication list containing papers (6) and patents (5) with Lee W. Page as an author. The papers include articles published in Tetrahedron Letters, Chem. Commun., Bioorganic & Medicinal Chemistry Letters, and Acta Crystallographica Section C and cover topics such as synthesis of fused bicyclic isoxazoles, amination of allenes, CB2 agonists for pain treatment, and COX-2 inhibitors. The patents relate to preparation of compounds for use as calcium channel or cannabinoid receptor modulators.
This document provides the official journal of the International Society of Nephrology, which includes the KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. The guideline was developed by an international work group to provide evidence-based recommendations on the diagnosis, evaluation, and treatment of anemia for patients with chronic kidney disease. It includes recommendations on the use of iron, erythropoiesis-stimulating agents, and red blood cell transfusions to treat anemia in kidney disease. Tables, figures, and references are provided to support the recommendations and guidelines.
1. Christopher J. Aquino
(supplement to CV, Publications and Patents)
IBAT (diabetes/obesity)
Discovery ofa Highly Potent, Nonabsorbable Apical Sodium-Dependent Bile Acid Transporter
Inhibitor. Wu, Yulin; Aquino, Christopher J.; Cowan, David J.; Anderson, Don L.; Ambroso, Jeff L.;
Bishop, Michael J.; Boros, Eric E.; Chen, Lihong; Cunningham, Alan; Dobbins, Robert L.; et al. Journal
of Medicinal Chemistry (2013), 56(12), 5094-5114.
Synthesis and evaluation ofnon-absorbable ASBTinhibitors for the treatment oftype 2 diabetes.
Wu, Yulin; Aquino, Christopher; Cowan, David; Bishop, Michael J.; Yao, Bert; Chen, Lihong; Anderson,
Don; McIntyre, Maggie; Harston,Lindsey; Roller, Shane; et al. Abstracts of Papers,246th ACS National
Meeting & Exposition, Indianapolis, IN, United States,September 8-12, 2013 (2013), MEDI-267.
Benzothiazepine derivatives as ileal bile acid transporter (iBAT)inhibitors and their preparation
and use for the treatment ofmetabolic disorders. Aquino, Christopher Joseph; Collins, Jon Loren;
Cowan, David John; Wu, Yulin. PCT Int. Appl. (2011), WO 2011137135 A1 20111103.
FAS (cancer)
Preparation of triazolone derivatives and analogs for use as fatty acid synthase inhibitors. Adams,
Nicholas D.; Aquino, Christopher Joseph; Ghergurovich, Jonathan M.; Musso, David Lee; Parrish,
Cynthia A.; Reif, Alexander Joseph. PCT Int. Appl. (2012), WO 2012037299 A2 20120322.
Preparation of tetrazole derivatives and analogs for use as fatty acid synthase inhibitors. Aquino,
Christopher Joseph; Heyer,Dennis; Kiesow, Terence John; Musso, David Lee; Parrish,Cynthia A. PCT
Int. Appl. (2012), WO 2012037298 A1 20120322.
Triazolones as fatty acid synthase inhibitors and their preparation and use for the treatment of
cancer. Adams,Nicholas D.; Aquino, Christopher Joseph; Chaudhari, Amita M.; Ghergurovich,
Jonathan M.; Kiesow, Terence John; Parrish, Cynthia A.; Reif, Alexander Joseph; Wiggall, Kenneth.
PCT Int. Appl. (2011), WO 2011103546 A1 20110825.
CCR-5 (HIV)
Novel 4,4-Disubstituted Piperidine-Based C-C Chemokine Receptor-5 Inhibitors with High Potency
against Human Immunodeficiency Virus-1 and an Improved human Ether-a-go-go Related Gene
(hERG) Profile. Kazmierski, Wieslaw M.; Anderson, Don L.; Aquino, Christopher; Chauder, Brian A.;
Duan, Maosheng; Ferris, Robert; Kenakin, Terrence; Koble, Cecilia S.; Lang, Dan G.; McIntyre, Maggie
S.; et al. Journal of Medicinal Chemistry (2011), 54(11), 3756-3767.
2. Discovery ofBioavailable 4,4-Disubstituted Piperidines as Potent Ligands ofthe Chemokine
Receptor 5 and Inhibitors ofthe Human Immunodeficiency Virus-1. Kazmierski, Wieslaw M.;
Aquino, Christopher; Chauder, Brian A.; Deanda,Felix; Ferris, Robert; Jones-Hertzog, Deborah K.;
Kenakin, Terrence; Koble, Cecilia S.; Watson, Christian; Wheelan, Pat; et al. Journal of Medicinal
Chemistry (2008), 51(20), 6538-6546.
4,4-Disubstituted cyclohexylamine based CCR5 chemokine receptor antagonists as anti-HIV-1
agents. Duan,Maosheng; Aquino, Christopher; Dorsey, George F.; Ferris, Robert; Kazmierski, Wieslaw
M. Bioorganic & Medicinal Chemistry Letters (2009), 19(17), 4988-4992.
[2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal
of the piperidine ring. Duan,Maosheng; Aquino, Christopher; Ferris, Robert; Kazmierski, Wieslaw M.;
Kenakin, Terry; Koble, Cecilia; Wheelan, Pat; Watson, Chris; Youngman, Michael. Bioorganic &
Medicinal Chemistry Letters (2009), 19(6), 1610-1613.
Novel, potent and bioavailable CCR5 chemokine receptor small-molecule antagonists for HIV
therapy: Scaffold discovery and addressing hERG ion channel affinity in the process ofoptimizing
potency and bioavailability. Kazmierski, Wieslaw; Anderson, Don L.; Aquino, Chris J.; Bifulco, Neil;
Boone, Larry R.; Boros, Eric E.; Chauder, Brian A.; Chong, Pek Y.; Duan, Maosheng; Ferris, Robert G.;
et al. Abstracts of Papers,232nd ACS National Meeting, San Francisco, CA, United States,Sept. 10-14,
2006 (2006), MEDI-297.
Discovery and design ofpotent piperidine-based CCR5 antagonists for the potential treatment of
HIV-1 infection. Chauder,Brian A.; Anderson, Donald; Aquino, Christopher J.; Bifulco, Neil; Boone,
Lawrence R.; Boros,Eric E.; Chong, Pek Y.; Du, Kien S.; Duan, Maosheng; Ferris, Robert G.; et al.
Abstracts of Papers,232nd ACS National Meeting, San Francisco, CA,United States,Sept. 10-14, 2006
(2006), MEDI-242.
Design, synthesis and structure-activity relationship studies ofnovel 4,4-disubstituted piperidine
based CCR5 antagonists as anti-HIV-1 agents. Peckham,Jennifer; Anderson, Donald; Aquino, Chris;
Bifulco, Neil; Boone, Larry; Chong, Pek; Duan, Maosheng; Ferris, Robert; Kazmierski, Wieslaw;
Kenakin, Terry; et al. Abstracts of Papers,230th ACS National Meeting, Washington, DC,United States,
Aug. 28-Sept. 1, 2005 (2005), MEDI-059.
Preparation of pyrrolidine and azetidine compounds as CCR5 antagonists. Yang,Hanbiao;
Kazmierski, Wieslaw Mieczyslaw; Aquino, Christopher Joseph. PCT Int. Appl. (2004), WO 2004055016
A1 20040701.
Preparation of indane compounds and analogs as CCR5 antagonists. Youngman,Michael;
Kazmierski, Wieslaw Mieczyslaw; Yang, Hanbiao; Aquino, Christopher Joseph. PCT Int. Appl. (2004),
WO 2004055012 A1 20040701.
Preparation of oxazine and morpholine derivativesas CCR5 antagonists. Aquino, Christopher
Joseph; Chong, Pek Yong; Duan, Maosheng; Kazmierski, Wieslaw Mieczyslaw . PCT Int. Appl. (2004),
WO 2004055011 A1 20040701.
3. Preparation of aminoalkylaryl cyclopropyl compounds as CCR5 antagonists. Peckham,Jennifer
Poole; Aquino, Christopher Joseph; Kazmierski, Wieslaw Mieczyslaw. PCT Int. Appl. (2004), WO
2004055010 A2 20040701.
Preparation of benzimidazolylazabicyclooctylethylpiperidines as CCR5 antagonists for the
treatment ofHIVinfection. Kazmierski, Wieslaw Mieczyslaw; Aquino, Christopher Joseph; Bifulco,
Neil; Boros, Eric Eugene; Chauder, Brian Andrew; Chong, Pek Yoke; Duan, Maosheng; Deanda,Felix,
Jr.; Koble, Cecilia Suarez; Mclean, Ed Williams; et al. PCT Int. Appl. (2004), WO 2004054974 A2
20040701.
Preparation of heterocyclylalkyl substituted cyclohexyl compounds as CCR5 antagonists. Duan,
Maosheng; Kazmierski, Wieslaw Mieczyslaw; Aquino, Christopher Joseph. PCT Int. Appl. (2004), WO
2004054581 A2 20040701.
NNRTI (HIV)
Anti-HIVagents. Aquino, Christopher Joseph; Dickson, Hamilton; Peat,Andrew James. PCT Int. Appl.
(2008), WO 2008157273 A1 20081224.
Preparation of 1,3,4-oxadiazoles as a non-nucleoside reverse transcriptase inhibitor for treating
human immunodeficiency virus infection. Aquino, Christopher Joseph; Dickson, Hamilton; Peat,
Andrew James. PCT Int. Appl. (2008), WO 2008157330 A1 20081224.
Preparation of 2-({4-chloro-2-[(3-chloro-5-cyanophenyl)carbonyl]phenyl}oxy)-N-(4-{[(2S)-2,3-
dihydroxy-3-methylbutyl}oxy}-2-methylphenyl}acetamide as a non-nucleoside reverse transcriptase
inhibitor. Aquino, Christopher Joseph; Freeman, George Andrew; Martin, Michael Tolar. PCT Int.
Appl. (2007), WO 2007121415 A2 20071025.
Preparation of 2-({4-chloro-2-[(3-chloro-5-cyanophenyl)carbonyl]phenyl}oxy)-N-{3-fluoro-4-[(2-
hydroxy-2-methylpropyl)oxy]-2-methylphenyl}acetamide as a non-nucleoside reverse transcriptase
inhibitor. Aquino, Christopher Joseph; Freeman, George Andrew; Martin, Michael Tolar. PCT Int.
Appl. (2007), WO 2007121418 A2 20071025.
Preparation of 2-({4-chloro-2-[(3-chloro-5-cyanophenyl)carbonyl]phenyl}oxy)-N-{4-[(2,3-
dihydroxy-3-methylbutyl)oxy]-3-fluoro-2-methylphenyl}acetamide as a non-nucleoside reverse
transcriptase inhibitor. Aquino, Christopher Joseph; Freeman, George Andrew; Martin, Michael Tolar.
PCT Int. Appl. (2007), WO 2007121416 A2 20071025.
NPY Y5 (obesity)
Synthesis and structure activity relationship ofguanidines as NPYY5 antagonists. Aquino,
Christopher J.; Ramanjulu, Joshi M.; Heyer,Dennis; Daniels, Alejandro J.; Palazzo, Fabio; Dezube,
Milana. Bioorganic & Medicinal Chemistry (2004), 12(10), 2691-2708.
4. 2-Aminobenzimidazoles: A class oforally bioavailable and brain permeable neuropeptide YY5
antagonists. Heyer,Dennis; Akwabi-Ameyaw,Adwoa; Aquino, Christopher; Dezube, Milana; Fang,
Jing; Linn, James; Marron, Brian; Palazzo, Fabio; Ramanjulu, Joshi; Travis, Benjamin; et al. Abstracts of
Papers,222nd ACS National Meeting, Chicago, IL, United States, August 26-30, 2001 (2001), MEDI-
284.
Synthesis and SAR ofsubstituted 5-acylamino benzimidazoles as potent neuropeptide YY5
antagonists. Akwabi-Ameyaw,Adwoa; Heyer,Dennis; Aquino, Christopher; Fang, Jing; Ramanjulu,
Joshi; Travis, Benjamin; Burnette,Thimysta; Tong, Wei-Qin; Lyerly, Donald; Daniels, Alejandro.
Abstracts of Papers,222nd ACS National Meeting, Chicago, IL, United States, August 26-30, 2001
(2001), MEDI-033.
Benzimidazole neuropeptide YY5 antagonists:Rapid SAR development using a solid-phase
approach. Linn, James; Aquino, Christopher; Dezube, Milana; Heyer,Dennis; Marron, Brian; Travis,
Benjamin; Daniels, Alejandro. Abstracts of Papers,222nd ACS National Meeting, Chicago, IL, United
States,August 26-30, 2001 (2001), MEDI-027.
2-Aminobenzimidazoles as neuropeptide YY5 antagonists: Solution phase synthesis and structure-
activity relationships. Fang,Jing; Aquino, Christopher; Heyer,Dennis; Travis, Benjamin; Burnette,
Thimysta; Tong, Wei-Qing; Lyerly, Donald; Daniels, Alejandro. Abstracts of Papers,222nd ACS
National Meeting, Chicago, IL, United States, August 26-30, 2001 (2001), MEDI-026.
Synthesis and structure activity studies ofbisheteroaryl guandines as NPY-Y5 antagonists.
Ramanjulu, Joshi; Aquino, Chris; Palazzo, Fabio; Heyer,Dennis; Daniels, Alejandro; Burnette, Thimysta.
Abstracts of Papers, 221st ACS National Meeting, San Diego, CA, United States,April 1-5, 2001 (2001),
MEDI-210.
CCK-A (obesity)
Optimization of 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepinesas Potent, Orally Active CCK-A
Agonists. Henke,Brad R.; Aquino, Christopher J.; Birkemo, Larry S.; Croom, Dallas K.; Dougherty,
Robert W. Jr.; Ervin, Gregory N.; Grizzle, Mary K.; Hirst, Gavin C.; James,Michael K.; Johnson,
Michael F.; et al. Journal of Medicinal Chemistry (1997), 40(17), 2706-2725.
Discovery of1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist
activity. 1. Optimization of the agonist "trigger." Aquino, Christopher J.; Armour, Duncan R.;
Berman, Judd M.; Birkemo, Larry S.; Carr, Robin A. E.; Croom, Dallas K.; Dezube, Milana; Dougherty,
Robert W.,Jr.; Ervin, Gregory N.; et al. Journal of Medicinal Chemistry (1996), 39(2), 562-9.
Discovery of1,5-Benzodiazepineswith Peripheral Cholecystokinin (CCK-A)Receptor Agonist
Activity (II): Optimization of the C3 Amino Substituent. Hirst,Gavin C.; Aquino, Christopher;
Birkemo, Lawrence; Croom,Dallas K.; Dezube, Milana; Dougherty, Robert W., Jr.; Ervin, Gregory N.;
Grizzle, Mary K.; Hanke, Brad; et al. Journal of Medicinal Chemistry (1996), 39(26), 5236-5245.
5. Preparation of cholecystokinin and gastrin receptor-antagonist 1,5-benzodiazepindiones. Aquino,
Christopher Joseph; Dezube, Milana; Henke, Brad Richard; Brackeen,Marcus; Jeffs,Peter Walter; Suh,
Edward Martin; Hirst, Gavin Charles; Sugg, Elizabeth Ellen; Willson, Timothy Mark; Momtahen, Tanya.
PCT Int. Appl. (1995), WO 9528391 A1 19951026.
Preparation of 1,4-benzodiazepin-2-one-1-acetamides as cholecystokinin-A receptor agonists.
Aquino, Christopher Joseph; Dezube, Milana; Sugg, Elizabeth Ellen; Sherrill, Ronald George; Willson,
Timothy Mark; Szewczyk, Jerzy Ryszard. PCT Int. Appl. (1995), WO 9528399 A1 19951026.
Preparation of CCK or gastrin modulating 5-heterocyclyl-1,5-benzodiazepinediones. Aquino,
Christopher Joseph; Sugg, Elizabeth Ellen; Szewczyk, Jerzy Ryszard. PCT Int. Appl. (1995), WO
9528419 A1 19951026.
Preparation of 1,5-benzodiazepine-2,4-dione derivativesas cholecystokinin A receptor agonists.
Sugg, Elizabeth Ellen; Aquino, Christopher Joseph; Szewczyk, Jerzy Ryszard; Finch, Harry; Carr, Robin
Arthur Ellis. PCT Int. Appl. (1994), WO 9424149 A1 19941027.
Chemistry/Medicinal Chemistry
Protease substrate mapping. Green,Michael; McGeehan, Gerard M.; Anderegg, Robert S.; Bickett, D.
Mark; Kassel,Daniel; Aquino, Christopher J.; Sugg, Elizabeth E.; Millington, David S.; Norwod, Daniel
L.; et al. Innovation Perspect. Solid Phase Synth. Collect. Pap.,Int. Symp., 3rd (1994), 239-44.
Amidrazones. 10. Stevens rearrangement of1-benzyl and 1-allyl-substituted-3-amino-4,5-dihydro-
1-phenyl-1H-pyrazolium bromides. Smith, Richard F.; Aquino, Christopher J.; Olson, Laurie A.;
Galante, Julienne M.; Liptak, Stephen C. Tetrahedron Letters (1985), 26(46), 5663-6.